Mario Castro1, Toni Schweiger2, Huiquing Yin-DeClue2, Thiruvamoor P Ramkumar2, Chandrika Christie2, Jie Zheng3, Rebecca Cohen2, Kenneth B Schechtman3, Robert Strunk4, Leonard B Bacharier4. 1. Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Washington University School of Medicine, St Louis, Mo. Electronic address: castrom@wustl.edu. 2. Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Washington University School of Medicine, St Louis, Mo. 3. Department of Biostatistics, Washington University School of Medicine, St Louis, Mo. 4. Department of Pediatrics, Washington University School of Medicine, St Louis, Mo.
Abstract
BACKGROUND: Immune response after viral infection usually involves T(H)1-mediated response; however, severe respiratory syncytial virus (RSV) infection appears to be associated with the development of asthma, a T(H)2-predominant phenotype. OBJECTIVE: To understand the early and subsequent immunologic response to a serious RSV infection in children over time. METHODS: A total of 206 previously healthy infants hospitalized with severe RSV bronchiolitis were enrolled in a prospective cohort called the RSV Bronchiolitis in Early Life study. Peripheral blood T cells were obtained immediately after RSV infection and at 2, 4, and 6 years of age, stimulated with phorbol 12-myristate 13-acetate and ionomycin, and analyzed for IL-2, IL-4, IL-13, and IFN-gamma by flow cytometry and real-time PCR. RESULTS: Of the children, 48% (n = 97) developed asthma (physician-diagnosed), and 48% (n = 97) had eczema by age 6 years; 32% (n = 48 of 150) developed allergic sensitization by 3 years of age. Children with asthma had lower IL-13 expression at 6 years of age than those without (P = .001). IFN-gamma, IL-2, and IL-4 levels did not differ by asthma or eczema status during follow-up (all P > .05). Allergic sensitization was not associated with differences in cytokine levels during follow-up (all P > .05). CONCLUSION: Severe RSV infection early in life is associated with a high incidence of asthma and eczema. Contrary to expectations, subsequent immunologic development in those who developed asthma, eczema, or allergic sensitization was not associated with a T(H)2 phenotype in the peripheral blood.
BACKGROUND: Immune response after viral infection usually involves T(H)1-mediated response; however, severe respiratory syncytial virus (RSV) infection appears to be associated with the development of asthma, a T(H)2-predominant phenotype. OBJECTIVE: To understand the early and subsequent immunologic response to a serious RSV infection in children over time. METHODS: A total of 206 previously healthy infants hospitalized with severe RSV bronchiolitis were enrolled in a prospective cohort called the RSV Bronchiolitis in Early Life study. Peripheral blood T cells were obtained immediately after RSV infection and at 2, 4, and 6 years of age, stimulated with phorbol 12-myristate 13-acetate and ionomycin, and analyzed for IL-2, IL-4, IL-13, and IFN-gamma by flow cytometry and real-time PCR. RESULTS: Of the children, 48% (n = 97) developed asthma (physician-diagnosed), and 48% (n = 97) had eczema by age 6 years; 32% (n = 48 of 150) developed allergic sensitization by 3 years of age. Children with asthma had lower IL-13 expression at 6 years of age than those without (P = .001). IFN-gamma, IL-2, and IL-4 levels did not differ by asthma or eczema status during follow-up (all P > .05). Allergic sensitization was not associated with differences in cytokine levels during follow-up (all P > .05). CONCLUSION:Severe RSV infection early in life is associated with a high incidence of asthma and eczema. Contrary to expectations, subsequent immunologic development in those who developed asthma, eczema, or allergic sensitization was not associated with a T(H)2 phenotype in the peripheral blood.
Authors: P G Holt; J B Clough; B J Holt; M J Baron-Hay; A H Rose; B W Robinson; W R Thomas Journal: Clin Exp Allergy Date: 1992-12 Impact factor: 5.018
Authors: G Del Prete; E Maggi; P Parronchi; I Chrétien; A Tiri; D Macchia; M Ricci; J Banchereau; J De Vries; S Romagnani Journal: J Immunol Date: 1988-06-15 Impact factor: 5.422
Authors: W M Comans-Bitter; R de Groot; R van den Beemd; H J Neijens; W C Hop; K Groeneveld; H Hooijkaas; J J van Dongen Journal: J Pediatr Date: 1997-03 Impact factor: 4.406
Authors: Eli Silver; Huiqing Yin-DeClue; Ken B Schechtman; Mitchell H Grayson; Leonard B Bacharier; Mario Castro Journal: Pediatr Allergy Immunol Date: 2008-12-22 Impact factor: 6.377
Authors: William T Shearer; Howard M Rosenblatt; Rebecca S Gelman; Rebecca Oyomopito; Susan Plaeger; E Richard Stiehm; Diane W Wara; Steven D Douglas; Katherine Luzuriaga; Elizabeth J McFarland; Ram Yogev; Mobeen H Rathore; Wende Levy; Bobbie L Graham; Stephen A Spector Journal: J Allergy Clin Immunol Date: 2003-11 Impact factor: 10.793
Authors: Hendrik Jan de Heer; Hamida Hammad; Thomas Soullié; Daniëlle Hijdra; Nanda Vos; Monique A M Willart; Henk C Hoogsteden; Bart N Lambrecht Journal: J Exp Med Date: 2004-07-05 Impact factor: 14.307
Authors: Kohei Hasegawa; Jonathan M Mansbach; Yury A Bochkov; James E Gern; Pedro A Piedra; Cindy S Bauer; Stephen J Teach; Susan Wu; Ashley F Sullivan; Carlos A Camargo Journal: JAMA Pediatr Date: 2019-06-01 Impact factor: 16.193
Authors: Leonard B Bacharier; Rebecca Cohen; Toni Schweiger; Huiquing Yin-Declue; Chandrika Christie; Jie Zheng; Kenneth B Schechtman; Robert C Strunk; Mario Castro Journal: J Allergy Clin Immunol Date: 2012-03-22 Impact factor: 10.793
Authors: Charles F Schuler; Carrie-Anne Malinczak; Shannon K K Best; Susan B Morris; Andrew J Rasky; Catherine Ptaschinski; Nicholas W Lukacs; Wendy Fonseca Journal: Allergy Date: 2020-05-15 Impact factor: 13.146